These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 31549066)

  • 21. Active immunization against complement factor C5a: a new therapeutic approach for Alzheimer's disease.
    Landlinger C; Oberleitner L; Gruber P; Noiges B; Yatsyk K; Santic R; Mandler M; Staffler G
    J Neuroinflammation; 2015 Aug; 12():150. PubMed ID: 26275910
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A multimeric immunogen for the induction of immune memory to beta-amyloid.
    Mantile F; Basile C; Cicatiello V; De Falco D; Caivano A; De Berardinis P; Prisco A
    Immunol Cell Biol; 2011 Jul; 89(5):604-9. PubMed ID: 21102534
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Precursor-Independent Overproduction of Beta-Amyloid in AD: Mitochondrial Dysfunction as Possible Initiator of Asymmetric RNA-Dependent βAPP mRNA Amplification. An Engine that Drives Alzheimer's Disease.
    Volloch V; Olsen BR; Rits S
    Ann Integr Mol Med; 2019; 1(1):61-74. PubMed ID: 31858090
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical trials of amyloid-based immunotherapy for Alzheimer's disease: end of beginning or beginning of end?
    Li Y; Liu Y; Wang Z; Jiang Y
    Expert Opin Biol Ther; 2013 Nov; 13(11):1515-22. PubMed ID: 24053611
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical Development of Aducanumab, an Anti-Aβ Human Monoclonal Antibody Being Investigated for the Treatment of Early Alzheimer's Disease.
    Budd Haeberlein S; O'Gorman J; Chiao P; Bussière T; von Rosenstiel P; Tian Y; Zhu Y; von Hehn C; Gheuens S; Skordos L; Chen T; Sandrock A
    J Prev Alzheimers Dis; 2017; 4(4):255-263. PubMed ID: 29181491
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alzheimer's disease and immunotherapy.
    Solomon B
    Curr Alzheimer Res; 2004 Aug; 1(3):149-63. PubMed ID: 15975063
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rifampicin is a candidate preventive medicine against amyloid-β and tau oligomers.
    Umeda T; Ono K; Sakai A; Yamashita M; Mizuguchi M; Klein WL; Yamada M; Mori H; Tomiyama T
    Brain; 2016 May; 139(Pt 5):1568-86. PubMed ID: 27020329
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of a DNA Aβ42 vaccine in adult rhesus monkeys (Macaca mulatta): antibody kinetics and immune profile after intradermal immunization with full-length DNA Aβ42 trimer.
    Lambracht-Washington D; Fu M; Frost P; Rosenberg RN
    Alzheimers Res Ther; 2017 Apr; 9(1):30. PubMed ID: 28441965
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tau immunotherapy modulates both pathological tau and upstream amyloid pathology in an Alzheimer's disease mouse model.
    Castillo-Carranza DL; Guerrero-Muñoz MJ; Sengupta U; Hernandez C; Barrett AD; Dineley K; Kayed R
    J Neurosci; 2015 Mar; 35(12):4857-68. PubMed ID: 25810517
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Are antibodies directed against amyloid-β (Aβ) oligomers the last call for the Aβ hypothesis of Alzheimer's disease?
    Panza F; Lozupone M; Dibello V; Greco A; Daniele A; Seripa D; Logroscino G; Imbimbo BP
    Immunotherapy; 2019 Jan; 11(1):3-6. PubMed ID: 30702009
    [No Abstract]   [Full Text] [Related]  

  • 31. Immunotherapy with Aducanumab Restores Calcium Homeostasis in Tg2576 Mice.
    Kastanenka KV; Bussiere T; Shakerdge N; Qian F; Weinreb PH; Rhodes K; Bacskai BJ
    J Neurosci; 2016 Dec; 36(50):12549-12558. PubMed ID: 27810931
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A vaccine against Alzheimer's disease: developments to date.
    Vickers JC
    Drugs Aging; 2002; 19(7):487-94. PubMed ID: 12182685
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The antimicrobial protection hypothesis of Alzheimer's disease.
    Moir RD; Lathe R; Tanzi RE
    Alzheimers Dement; 2018 Dec; 14(12):1602-1614. PubMed ID: 30314800
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Site-specific UBITh amyloid-beta vaccine for immunotherapy of Alzheimer's disease.
    Wang CY; Finstad CL; Walfield AM; Sia C; Sokoll KK; Chang TY; Fang XD; Hung CH; Hutter-Paier B; Windisch M
    Vaccine; 2007 Apr; 25(16):3041-52. PubMed ID: 17287052
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Amyloid beta peptide immunotherapy in Alzheimer disease.
    Delrieu J; Ousset PJ; Voisin T; Vellas B
    Rev Neurol (Paris); 2014 Dec; 170(12):739-48. PubMed ID: 25459121
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current Peptide Vaccine and Immunotherapy Approaches Against Alzheimer's Disease.
    Parrocha CMT; Nowick JS
    Pept Sci (Hoboken); 2023 Jan; 115(1):. PubMed ID: 36778914
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tau passive immunization inhibits not only tau but also Aβ pathology.
    Dai CL; Tung YC; Liu F; Gong CX; Iqbal K
    Alzheimers Res Ther; 2017 Jan; 9(1):1. PubMed ID: 28073379
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent advancements toward therapeutic vaccines against Alzheimer's disease.
    Herline K; Drummond E; Wisniewski T
    Expert Rev Vaccines; 2018 Aug; 17(8):707-721. PubMed ID: 30005578
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Toward an early diagnosis and treatment of Alzheimer's disease.
    Nordberg A
    Int Psychogeriatr; 2003 Sep; 15(3):223-37. PubMed ID: 14756159
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Amyloid-beta immunotherapy for Alzheimer's disease.
    Fu HJ; Liu B; Frost JL; Lemere CA
    CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):197-206. PubMed ID: 20205640
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.